Buzzkill Labs, developer of the rapid saliva test for psychoactive THC, announced the close of an oversubscribed series A funding round co-led by Poseidon Garden Ventures and existing investors. Buzzkill will use the proceeds from the financing to commercialize its technology, which fills employers' critical need to maintain safe workplaces while respecting the dignity of employees who legally use cannabis outside of work.

According to the company its proprietary technology performs on-site detection of psychoactive THC in saliva (oral fluid) samples in less than 15 minutes. The platform, initially deployed in workplace safety applications, enables employers with …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.